Protecting Patient Access to Cancer and Complex Therapies Act of 2025 (H.R. 4299)
The FSR has recently signed a letter applauding the introduction of the Protecting Patient Access to Cancer and Complex Therapies Act
of 2025 (H.R. 4299). In order to continue protecting the patient-provider relationship, this bill, which, if enacted, will address the untenable Part B payment cuts to healthcare providers included in the Inflation Reduction Act (IRA), and protect
Medicare beneficiaries’ access to lifesaving therapies.
Request for favorable coverage of AVISE® Lupus test in Medical Policy #05-86000-22 titled “Tumor/Genetic Markers”
Many FSR leaders also signed onto a letter sent to Florida Blue addressing a key statement in the current
Florida Blue’s medical policy that includes AVISE® Lupus testing and requests consideration in covering this important test.
The statement, “The evidence is insufficient to determine that the technology results in an improvement in the
net health outcome.” does not align with the breadth and quality of published, peer-reviewed evidence.
As rheumatologists working daily to diagnose and manage systemic lupus erythematosus (SLE), we believe the data clearly demonstrate that
AVISE Lupus improves net health outcomes through more accurate and timely diagnosis, better-informed treatment decisions, and reduced unnecessary healthcare utilization.
At the 2025 CSRO Advocacy Conference, FSR Board Member and Past President Dr. Robert Levin moderates a panel on the powerful role of Pharmacy Benefit Managers (PBMs) in drug pricing, patient access, and physician freedom. Panelists Chuck Melendi and Ryan
Rice discuss how PBMs profit from higher list prices, the impact of policy reforms, and why collaboration is key to fixing a broken system. Video provided by Disruptive Dialogue With Chuck Melendi
